

## Drug Utilization Review Board Meeting

**September 19, 2013**

Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
<b>New Drug Reviews</b>			
<b>Anticoagulant</b>			
	Eliquis (Oral) Tablet	NP/PA	NP/PA
Coumadin (Oral) Tablet changes from NP status to P status.			
<b>Short Bowel Syndrome</b>			
	Gattex (Subcutaneous) Kit	NP/PA	NP/PA
<b>Antihyperlipidemics for Homozygous Familial Hypercholesterolemia</b>			
	Juxtapid (Oral) Capsule	NP/PA	NP/PA
	Kynamro (Subcutaneous) Syringe	NP/PA	NP/PA
<b>Urea Cycle Disorder</b>			
	Ravicti (Oral) Liquid	NP/PA	NP/PA
<b>Antihyperlipidemic for Hypertriglyceridemia</b>			
	Vascepa (Oral) Capsule	NP/PA	NP/PA

NP = non-preferred/ P = preferred/ PA = prior authorization

### **Therapeutic Class Reviews**

The following classes were reviewed with recommendations for changes in PDL status for the following drugs:

#### **Analgesics, Opioid Abuse, Buprenorphine-Naloxone Agents**

Zubsolv (Sublingual) Tablet – changes from NP/PA status to P/PA status.

#### **Antivirals, Influenza Agents**

Rimantadine (Oral) Tablet - changes from P status to NP status.